Skip to main content
SpringerLink
Log in

The Role of Progestogens in Regulating Matrix Metalloproteinase Activity in Macrophages and Microglial Cells

Neurochemical Research Aims and scope Submit manuscript

Abstract

Although the systemic effects of progestogens have been extensively studied, little is known in regards to the cellular effects of these compounds. Using a cellular model for vascular (macrophages) and brain (microglial) cells, we studied the effects of various progestogens, either alone or in combination with 17β-estradiol (E2) on the activity of matrix metalloproteinase-9 (MMP-9), a proteolytic enzyme involved in vascular remodeling and plaque destabilization in cardiovascular events, blood–brain barrier breakdown in stroke and brain regeneration and neurovascular remodeling during repair phases of brain injury. In the absence of E2, medroxyprogesterone acetate (MPA), a synthetic progestogen and progesterone (PG) metabolites tended to increase MMP-9 enzyme activity in macrophages and microglial cells, whereas PG decreased such activity in macrophages; exceptions being that MPA and the PG metabolite, pregnanediol (Pdiol) had no effect on macrophage MMP-9 enzyme activity and PG had no effect on microglial cell MMP-9 enzyme activity. In the presence of E2, an opposite affect was observed whereby MPA and the PG metabolites tended to decrease MMP-9 enzyme activity from macrophages and microglial cells, whereas PG had no effect; exceptions being that MPA and Pdiol had no effect on macrophage MMP-9 enzyme activity. In conclusion, these results demonstrate that the effects of PG, PG metabolites and MPA on MMP-9 enzyme activity differ across vascular and brain cells when administered alone or in combination with E2 which could have important mechanistic implications for hormone therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL (1990) Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41:399–410

    Article  PubMed  CAS  Google Scholar 

  2. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273:199–208

    Article  Google Scholar 

  3. de Lignières B (2002) Effects of progestogens on the postmenopausal breast. Climacteric 5:229–235

    PubMed  Google Scholar 

  4. Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A (2006) Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis 189:76–82

    Article  PubMed  CAS  Google Scholar 

  5. Mueck AO, Seeger H, Wallwiener D (2002) Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 9:273–281

    Article  PubMed  Google Scholar 

  6. Potier M, Karl M, Elliot SJ, Striker GE, Striker LJ (2003) Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. Am J Physiol Endocrinol Metab 285:E1237–E1245

    PubMed  CAS  Google Scholar 

  7. Busti C, Falcinelli E, Momi S, Gresele P (2010) Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 5:13–25

    Article  PubMed  Google Scholar 

  8. Adibhatla RM, Hatcher JF (2008) Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 7:234–253

    Article  Google Scholar 

  9. Lincoln DW, Phillips PG, Bove K (2003) Estrogen-induced Ets-1 promotes capillary formation in an in vitro tumor angiogenesis model. Breast Cancer Res Treat 78:167–178

    Article  PubMed  CAS  Google Scholar 

  10. Wingrove CS, Garr E, Godsland IF, Stevenson JC (1998) 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1406:169–174

    PubMed  CAS  Google Scholar 

  11. Lee YJ, Lee EB, Kwon YE, Lee JJ, Cho WS, Kim HA, Song YW (2003) Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproteinase-1 in osteoarthritis chondrocytes. Rheumatol Int 23:282–288

    Article  PubMed  CAS  Google Scholar 

  12. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER (2003) Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 23:1633–1646

    Article  PubMed  CAS  Google Scholar 

  13. Zhang J, Salamonsen LA (2002) In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87:2346–2351

    Article  PubMed  CAS  Google Scholar 

  14. Kanca H, Walter I, Miller I, Schäfer-Somi S, Izgur H, Aslan S (2011) Expression and activity of matrix metalloproteinases in the uterus of bitches after spontaneous and induced abortion. Reprod Domest Anim 46:197–204

    Article  PubMed  CAS  Google Scholar 

  15. Singh M (2006) Progesterone-induced neuroprotection. Endocrine 29:271–274

    Article  PubMed  CAS  Google Scholar 

  16. Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L (2008) Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 55:128–138

    Article  Google Scholar 

  17. Nilsen J, Brinton RD (2002) Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143:205–212

    Article  PubMed  CAS  Google Scholar 

  18. Wang JM, Johnston PB, Ball BG, Brinton RD (2006) The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25:4706–4718

    Article  Google Scholar 

  19. Lorenzi S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease. Neurochem Int 43:191–196

    Article  Google Scholar 

  20. Bruno MA, Mufson EJ, Wuu J, Cuello AC (2009) Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 68:1309–1318

    Article  PubMed  CAS  Google Scholar 

  21. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 5:212–224

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was funded in part by Columbia Labs.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Ave., PSC 612, Los Angeles, CA, 90033, USA

    Juliana Hwang-Levine & Howard N. Hodis

  2. Atherosclerosis Research Unit, Departments of Medicine and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA

    Juliana Hwang-Levine & Howard N. Hodis

  3. Reproductive Research Laboratory, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA

    Frank Z. Stanczyk

Authors
  1. Juliana Hwang-Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Z. Stanczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard N. Hodis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliana Hwang-Levine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hwang-Levine, J., Stanczyk, F.Z. & Hodis, H.N. The Role of Progestogens in Regulating Matrix Metalloproteinase Activity in Macrophages and Microglial Cells. Neurochem Res 36, 1870–1875 (2011). https://doi.org/10.1007/s11064-011-0508-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-011-0508-0

Keywords

search

Navigation